The RBV Capital Fund, created with the participation of capital RVC and R-Pharm, invested 105 million rubles in PanDx, which is developing a multifunctional catheter “Izikat” for the treatment of severe diseases of the gastrointestinal tract. Investment officer at RBV Capital Fund Igor Honain will be part of the Board of Directors PanDx.
The leading indication for the use of the catheter is acute pancreatitis of medium and severe forms. The device is able to isolate a certain area of the GI tract while maintaining patency and maintaining the main functions of the GI tract. At the same time, a catheter can be used to collect biomaterials for the diagnosis of cancer of the pancreas and liver, as well as for the monitoring of diseases of the gastrointestinal tract.
According to PanDx, the device has undergone preliminary clinical testing, patent applications have been filed for the design, functionality and application of “Izikat” in the diagnosis and treatment of diseases of the GI tract and hepatobiliary system, as well as in other therapeutic areas.
RBV Capital is a specialized venture capital Fund established in 2014 to invest in innovative biomedical projects around the world. RBV Capital creates a diversified portfolio of breakthrough projects in the early stages of development. The investment strategy of the oriekhkh Fund is focused on innovative scientific developments aimed at solving the most important medical problems and implemented by strong teams with a clear vision of the goal.